查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790217

美国动物感染疾病物市场规模、份额和趋势分析报告：按动物、产品、给药途径、类型、分销管道和细分市场预测，2025 年至 2033 年

U.S. Veterinary Anti-infectives Market Size, Share & Trends Analysis Report By Animal, By Product, By Route Of Administration, By Type, By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国动物感染疾病市场概况

美国兽用感染疾病物市场规模预计在 2024 年为 22.3 亿美元，预计到 2033 年将达到 35.5 亿美元，2025 年至 2033 年的复合年增长率为 5.4%。预计推动市场发展的关键因素包括感染疾病的增加、研发倡议的增加、推动谨慎使用抗生素、开发新型治疗方法以及扩大人工智慧 (AI) 的应用。

由于人们对通用动物和牲畜的抗生素抗药性 (AMR) 日益担忧，美国兽用感染疾病市场正在经历重大变革时期。 《新闻医学》杂誌 2025 年 1 月的一项研究强调了家犬如何携带和传播抗生素抗药性沙门氏菌，从而增加了人畜共患感染疾病的风险。这提高了兽医和饲主的认识，推动了对伴侣动物领域更有针对性和更安全的抗感染疾病解决方案的需求。兽医实践对频谱抗生素的滥用越来越谨慎，促使人们对窄频谱药物、抗药性缓解疗法，甚至益生菌等预防性护理选择产生了兴趣。这种趋势也刺激了兽医诊断的发展，特别是药敏测试，它有助于制定负责任的治疗决策。

减少对抗生素依赖的技术创新正在进一步塑造畜牧业市场。宾州州立大学 2024 年 12 月的一项研究揭示了一种使用噬菌体代替抗生素治疗乳牛乳房炎的有前景的新治疗方法。这项开创性的研究凸显了替代抗生素疗法的市场不断扩大，包括噬菌体疗法、免疫调节剂、胜肽和其他生技药品。美国食品药物管理局和美国农业部对食用动物常规使用抗生素施加监管压力，这增加了此类替代抗生素的采用，尤其是在乳品加工业和牛肉生产商中。这些相关人员现在要求有效的治疗方法符合抗菌管理指南，同时保持牛健康和生产力，从而导致兽用感染疾病的范围超越传统抗生素。

同时，美国兽医协会 (AVMA) 强调兽医与饲主就负责任的抗生素使用进行沟通的重要性。这种以管理主导的方法正在重塑美国兽医实践的配药行为。随着兽医优先考虑诊断驱动的治疗并减少经验性抗生素使用，对诊断、药敏试验和更复杂的抗感染疗法的需求正在增长。製药公司正在透过开发符合管理原则的精准医疗和教育资源来应对这一变化。这种转变确保了更好的健康结果，并推动了市场对兽用感染疾病物创新的持续需求。

摘要：美国市场受三大驱动力驱动：伴侣动物抗菌药物抗药性威胁的发现、牲畜疾病非抗生素疗法的出现以及兽医管理文化的日益发展。这些因素正推动企业实现产品系列多元化，投资研发更安全的替代品，并开发支持负责任抗生素使用的工具。因此，市场正迅速朝精准化、永续性和创新性方向发展，共同对抗抗菌药物抗药性。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国动物感染疾病物市场趋势与展望

  • 市场体系展望
    • 母市场
    • 子公司市场
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 美国动物感染疾病物市场分析工具
    • 产业分析—波特五力分析
    • PESTEL分析
    • 主要国家的法规结构
    • 按主要国家和物种分類的动物族群估计数（2021-2023 年）
    • 重大感染疾病（主要种类）流行情形（2024年）
    • COVID-19影响分析

第四章美国动物感染疾病物市场：依种类、估计和趋势分析

  • 细分仪表板
  • 美国动物感染疾病物市场：动物变异分析
  • 美国动物感染疾病物市场规模及趋势分析（依动物种类，2021-2033）
  • 家畜
    • 家禽
    • 猪
    • 牛
    • 绵羊和山羊
    • 鱼
    • 其他的
  • 伴侣动物
    • 狗
    • 猫
    • 其他的

第五章美国动物感染疾病物市场：产品、估计与趋势分析

  • 细分仪表板
  • 美国动物感染疾病物市场：产品差异分析
  • 美国动物感染疾病物市场规模及趋势分析（依产品，2021-2033）
  • 抗菌剂
    • 头孢菌素类
    • 四环霉素
    • 青霉素
    • 大环内酯类
    • 其他（对苯二酚、磺胺类药物、多粘菌素）
  • 抗真菌药物
  • 抗病毒药物
  • 其他的

第六章：美国动物感染疾病物市场依给药途径、估计及趋势分析

  • 细分仪表板
  • 美国动物感染疾病物市场：给药途径变化分析
  • 美国动物感染疾病物市场规模及趋势分析（依给药途径，2021-2033）
    • 口服
    • 注射
    • 其他的

第七章：美国动物感染疾病物市场类型、估计与趋势分析

  • 细分仪表板
  • 美国动物感染疾病物市场：按类型变化分析
  • 美国动物感染疾病物市场规模及趋势分析（2021-2033）
    • 非处方药
    • 处方笺

第八章：动物感染疾病物市场：按分销管道进行的估计和趋势分析

  • 细分仪表板
  • 美国动物感染疾病物市场：通路波动分析
  • 美国动物感染疾病物市场规模及通路趋势分析（2021-2033）
    • 医院/诊所药房
    • 零售药局
    • 电子商务

第九章 竞争态势

  • 市场参与企业分类
  • 企业市场分析/堆图分析
  • 公司简介
    • Zoetis
    • Boehringer Ingelheim
    • Merck & Co. Inc.
    • Dechra Pharmaceuticals Plc.
    • Elanco Animal Health
    • Ceva Sante Animale
    • Virbac
    • Biogenesis Bago
    • Vetoquinol
    • Calier
    • Norbrook Laboratories
  • 战略地图
    • 合併与收购
    • 伙伴关係和合作
    • 扩张
    • 产品发布
    • 产品核可
    • 其他的
  • 主要企业名单
    • 製造商列表
    • 经销商名单
Product Code: GVR-4-68040-656-7

U.S. Veterinary Anti-infectives Market Summary

The U.S. veterinary anti-infectives market was estimated at USD 2.23 billion in 2024 and is projected to reach USD 3.55 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. Key factors expected to drive the market include the rise in animal infectious diseases, increasing R&D initiatives, a boost to prudent antibiotic use, development of novel treatments, and growing applications of Artificial Intelligence (AI).

The veterinary anti-infectives market in the U.S. is undergoing a significant transformation, driven by rising concerns over antimicrobial resistance (AMR) in companion animals and livestock. A January 2025 study highlighted in News-Medical underscores how household dogs can harbor and transmit antibiotic-resistant Salmonella, elevating the risk of zoonotic infections. This has raised awareness among veterinarians and pet owners, leading to a growing demand for more targeted and safer anti-infective solutions in the companion animal segment. Veterinary practices are increasingly cautious about the indiscriminate use of broad-spectrum antibiotics, prompting interest in narrow-spectrum drugs, resistance-mitigating therapies, and even preventive care options like probiotics. This trend also fuels the growth of veterinary diagnostics, especially for susceptibility testing that helps guide treatment decisions responsibly.

Innovations to reduce antibiotic reliance further shape the market in the livestock sector. A Penn State study from December 2024 revealed a promising new treatment for mastitis in dairy cows using bacteriophages instead of antibiotics. This breakthrough highlights the expanding market for antibiotic alternatives, including phage therapies, immunomodulators, peptides, and other biologics. Regulatory pressure from the FDA and USDA to curb routine antibiotic use in food-producing animals has increased the adoption of such alternatives, especially among dairy and beef producers. These stakeholders are now seeking effective treatments that comply with antimicrobial stewardship guidelines while maintaining herd health and productivity, thus broadening the veterinary anti-infectives landscape beyond conventional antibiotics.

Meanwhile, the American Veterinary Medical Association (AVMA) has emphasized the importance of communication between veterinarians and animal owners around responsible antibiotic use. This stewardship-led approach is reshaping prescribing behavior across U.S. veterinary practices. As veterinarians prioritize diagnosis-driven treatments and reduce empirical antibiotic use, there is an increasing demand for diagnostics, sensitivity testing, and more refined anti-infective therapies. Pharmaceutical companies are responding by developing precision drugs and educational resources that align with stewardship principles. This shift ensures better health outcomes and drives sustained market demand for innovation in veterinary anti-infectives.

In summary, the U.S. market is propelled by three major forces: the detection of AMR threats in pets, the emergence of non-antibiotic treatments for livestock diseases, and a growing culture of veterinary stewardship. These factors drive market players to diversify product portfolios, invest in R&D for safer alternatives, and develop tools supporting responsible antibiotic use. The result is a market rapidly evolving toward precision, sustainability, and innovation in the fight against antimicrobial resistance.

U.S. Veterinary Anti-infectives Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. veterinary anti-infectives market report based on animal, product, route of administration, type, and distribution channel.

  • Animal Outlook (Revenue, USD Million, 2021 - 2033)
  • Livestock Animal
    • Poultry
    • Swine
    • Cattle
    • Sheep & Goats
    • Fish
    • Others
  • Companion Animal
    • Dogs
    • Cats
    • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Antimicrobial
    • Tetracyclines
    • Penicillin
    • Cephalosporins
    • Macrolides
    • Quinolones
    • Others
  • Antifungals
  • Antivirals
  • Antiparasitic
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Injectable
  • Topical
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • OTC
  • Prescription
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital/ Clinic Pharmacy
  • Retail Pharmacies
  • E-commerce

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Country Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Anti-infectives Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rise in Infectious Diseases Among Animals
      • 3.2.1.2. Growing Research Initiatives
      • 3.2.1.3. Increasing R&D Initiatives
      • 3.2.1.4. Development Of Novel Treatments
      • 3.2.1.5. Increasing Regulatory Approvals
      • 3.2.1.6. Growing Applications of AI
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Drop in Consumption
      • 3.2.2.2. Emerging Drug Resistance
      • 3.2.2.3. Stringent Regulations
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Veterinary Anti-infectives Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework by Key Countries
    • 3.3.4. Estimated Animal Population, by Key Species, by Key Countries, 2021 - 2023
    • 3.3.5. Prevalence of Key Infectious Diseases, by key species, (2024)
    • 3.3.6. COVID-19 Impact Analysis

Chapter 4. U.S. Veterinary Anti-infectives Market: Animal Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Veterinary Anti-infectives Market: Animal Movement Analysis
  • 4.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by animal, 2021 to 2033 (USD Million)
  • 4.4. Livestock Animal
    • 4.4.1. Production Animal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Poultry
      • 4.4.2.1. Poultry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Swine
      • 4.4.3.1. Swine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Cattle
      • 4.4.4.1. Cattle Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Sheep & Goats
      • 4.4.5.1. Sheep & Goats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.6. Fish
      • 4.4.6.1. Fish Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.7. Others
      • 4.4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Companion Animal
    • 4.5.1. Companion Animal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Dogs
      • 4.5.2.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Cats
      • 4.5.3.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Veterinary Anti-infectives Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Veterinary Anti-infectives Market: Product Movement Analysis
  • 5.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
  • 5.4. Antimicrobials
    • 5.4.1. Antimicrobials Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Cephalosporins
      • 5.4.2.1. Cephalosporins Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Tetracyclines
      • 5.4.3.1. Tetracyclines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.4. Penicillin
      • 5.4.4.1. Penicillin Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.5. Macrolides
      • 5.4.5.1. Macrolides Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.6. Others (Quinoles, sulfonamides, polymyxins)
      • 5.4.6.1. Others (Quinoles, sulfonamides, polymyxins) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Antifungals
    • 5.5.1. Antifungals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Antivirals
    • 5.6.1. Antivirals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Veterinary Anti-infectives Market: By Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Veterinary Anti-infectives Market: By Route of Administration Movement Analysis
  • 6.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by route of administration, 2021 to 2033 (USD Million)
    • 6.3.1. Oral
      • 6.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Injectables
      • 6.3.2.1. Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Others
      • 6.3.3.1. Topical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Veterinary Anti-infectives Market: By Type Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Veterinary Anti-infectives Market: By Type Movement Analysis
  • 7.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by type, 2021 to 2033 (USD Million)
    • 7.3.1. OTC
      • 7.3.1.1. OTC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Prescription
      • 7.3.2.1. Prescription Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Veterinary Anti-infectives Market: By Distribution Channel Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. U.S. Veterinary Anti-infectives Market: By Distribution Channel Movement Analysis
  • 8.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
    • 8.3.1. Hospital/Clinic Pharmacy
      • 8.3.1.1. Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.2. Retail Pharmacies
      • 8.3.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.3. E-commerce
      • 8.3.3.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heap Map Analysis
  • 9.3. Company Profiles
    • 9.3.1. Zoetis
      • 9.3.1.1. Participant's Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Boehringer Ingelheim
      • 9.3.2.1. Participant's Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Merck & Co. Inc.
      • 9.3.3.1. Participant's Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Dechra Pharmaceuticals Plc.
      • 9.3.4.1. Participant's Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Elanco Animal Health
      • 9.3.5.1. Participant's Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Ceva Sante Animale
      • 9.3.6.1. Participant's Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Virbac
      • 9.3.7.1. Participant's Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Biogenesis Bago
      • 9.3.8.1. Participant's Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Vetoquinol
      • 9.3.9.1. Participant's Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Calier
      • 9.3.10.1. Participant's Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Norbrook Laboratories
      • 9.3.11.1. Participant's Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Product Benchmarking
      • 9.3.11.4. Strategic Initiatives
  • 9.4. Strategy Mapping
    • 9.4.1. Mergers & Acquisitions
    • 9.4.2. Partnerships & Collaborations
    • 9.4.3. Expansion
    • 9.4.4. Product launch
    • 9.4.5. Product Approval
    • 9.4.6. Others
  • 9.5. List of Key Companies
    • 9.5.1. List of Manufacturers
    • 9.5.2. List of Distributors

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Veterinary Anti-infectives Market, By Animal, 2021 - 2033 (USD Million)
  • Table 4 U.S. Veterinary Anti-infectives Market, By Livestock, 2021 - 2033 (USD Million)
  • Table 5 U.S. Veterinary Anti-infectives Market, By Companion Animal, 2021 - 2033 (USD Million)
  • Table 6 U.S. Veterinary Anti-infectives Market, By Product, 2021 - 2033 (USD Million)
  • Table 7 U.S. Veterinary Anti-infectives Market, By Antimicrobial, 2021 - 2033 (USD Million)
  • Table 8 U.S. Veterinary Anti-infectives Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 9 U.S. Veterinary Anti-infectives Market, By Type, 2021 - 2033 (USD Million)
  • Table 10 U.S. Veterinary Anti-infectives Market, By Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Veterinary Anti-infectives Market, Market Segmentation
  • Fig. 8 Market Driver Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Regional Marketplace: Key Takeaways
  • Fig. 14 U.S. Veterinary Anti-infectives Market, for Animal, 2021 - 2033 (USD Million)
  • Fig. 15 U.S. Veterinary Anti-infectives Market, for Livestock Animal, 2021 - 2033 (USD Million)
  • Fig. 16 U.S. Veterinary Anti-infectives Market, for Poultry, 2021 - 2033 (USD Million)
  • Fig. 17 U.S. Veterinary Anti-infectives Market, for Swine, 2021 - 2033 (USD Million)
  • Fig. 18 U.S. Veterinary Anti-infectives Market, for Cattle, 2021 - 2033 (USD Million)
  • Fig. 19 U.S. Veterinary Anti-infectives Market, for Sheep & Goats, 2021 - 2033 (USD Million)
  • Fig. 20 U.S. Veterinary Anti-infectives Market, for Fish, 2021 - 2033 (USD Million)
  • Fig. 21 U.S. Veterinary Anti-infectives Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 22 U.S. Veterinary Anti-infectives Market, for Companion Animal, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. Veterinary Anti-infectives Market, for Dogs, 2021 - 2033 (USD Million)
  • Fig. 24 U.S. Veterinary Anti-infectives Market, for Cats, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. Veterinary Anti-infectives Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. Veterinary Anti-infectives Market, for Product, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. Veterinary Anti-infectives Market, for Antimicrobial, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. Veterinary Anti-infectives Market, for Tetracyclines, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. Veterinary Anti-infectives Market, for Penicillin, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Veterinary Anti-infectives Market, for Cephalosporins, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. Veterinary Anti-infectives Market, for Macrolides, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. Veterinary Anti-infectives Market, for Quinolones, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. Veterinary Anti-infectives Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. Veterinary Anti-infectives Market, for Antifungals, 2021 - 2033 (USD Million)
  • Fig. 35 U.S. Veterinary Anti-infectives Market, for Antivirals, 2021 - 2033 (USD Million)
  • Fig. 36 U.S. Veterinary Anti-infectives Market, for Antiparasitic, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Veterinary Anti-infectives Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 38 U.S. Veterinary Anti-infectives Market, for Route of Administration, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. Veterinary Anti-infectives Market, for Oral, 2021 - 2033 (USD Million)
  • Fig. 40 U.S. Veterinary Anti-infectives Market, for Injectable, 2021 - 2033 (USD Million)
  • Fig. 41 U.S. Veterinary Anti-infectives Market, for Topical, 2021 - 2033 (USD Million)
  • Fig. 42 U.S. Veterinary Anti-infectives Market, for Type, 2021 - 2033 (USD Million)
  • Fig. 43 U.S. Veterinary Anti-infectives Market, for OTC, 2021 - 2033 (USD Million)
  • Fig. 44 U.S. Veterinary Anti-infectives Market, for Prescription, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. Veterinary Anti-infectives Market, for Distribution Channel, 2021 - 2033 (USD Million)
  • Fig. 46 U.S. Veterinary Anti-infectives Market, for Hospital/ Clinic Pharmacy, 2021 - 2033 (USD Million)
  • Fig. 47 U.S. Veterinary Anti-infectives Market, for Retail Pharmacies, 2021 - 2033 (USD Million)